Abstract: The invention relates to a pharmaceutical composition comprising (i) granules comprising Nilotinib, preferably in crystalline form, or a physiologically acceptable salt and/or solvate thereof, preferably crystalline anhydrous Nilotinib hydrochloride or crystalline Nilotinib hydrochloride monohydrate; and (ii) an extragranular phase comprising a surfactant, preferably poloxamer. The granules are preferably dry granulated.

Abstract: The invention relates to a process for the preparation of a dimethyl-C17-32-alkyl sulfonium salt, preferably a dimethyl-C17-32-alkyl sulfonium halide, more preferably a dimethyl-C17-32-alkyl sulfonium chloride, still more preferably dimethyl octadecyl sulfonium chloride, the process comprising the steps of: providing a mixture of a C17-32-alkyl halide and dimethyl sulfide; and reacting the C17-32-alkyl halide with the dimethyl sulfide.

Abstract: The invention relates to trialkyl sulfonium salts, compositions comprising the trialkyl sulfonium salts, agricultural compositions comprising such compositions, to the use of the trialkyl sulfonium salts and of the compositions as pesticide, preferably as fungicide, and to methods for controlling or combating pests and/or improving plant health by means of the trialkyl sulfonium salts and the compositions.

Abstract: The invention relates to a trialkyl sulfonium chloride, compositions comprising the trialkyl sulfonium chloride, agricultural compositions comprising such compositions and trialkyl sulfonium chloride, respectively, to the use of the trialkyl sulfonium chloride and of the compositions as a pesticide, preferably as a fungicide, and to methods for controlling or combating pests and/or improving plant health by means of the trialkyl sulfonium chloride and compositions.

Abstract: The invention relates to nanoparticles comprising Enzalutamide, processes for the preparation of such nanoparticles, pharmaceutical compositions and pharmaceutical dosage forms comprising such nanoparticles, processes for the preparation of such pharmaceutical dosage forms, and uses of the pharmaceutical dosage forms for medical purposes.

Abstract: Acid addition salts of 2-acetoxy-5-(?-cyclopropylcarbonyl-2-fluorobenzyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine with sulfuric acid or sulfonic acids, pharmaceutical compositions comprising the same and processes for the production thereof. The acid addition salts have a low toxicity.

Abstract: Morphologically stabilized amorphous aripiprazole and process for preparing the same.

Abstract: Morphologically stabilized amorphous aripiprazole and process for preparing the same.

Abstract: The present invention relates to an adsorbate, comprising an adsorbent and bicalutamide adsorbed on said adsorbent, a process for preparing same, and a pharmaceutical composition thereof.

Abstract: Morphologically stabilized amorphous aripiprazole and process for preparing the same.

Abstract: The present invention relates to a process for the preparation of topiramate, intermediates in this process and a process for the preparation of these intermediates.

Abstract: The invention relates to a process for preparing N-(4?-cyano-3?-trifluoromethylphenyl)-3-(4?-fluorophenylsulfonyl)-2-hydroxy-2-methylpropionamide (bicalutamide).

Abstract: Morphologically stabilized amorphous aripiprazole and process for preparing the same.

Abstract: A process for the side-chain bromination of alkylbenzenes according to Formula (I) wherein R1 is C1-C6-alkyl; R2 is H or C1-C6-alkyl which can be unsubstituted or substituted by one or more cyano groups; R3 is H or C1-C6-alkyl which can be unsubstituted or substituted by one or more cyano groups; comprising the steps of (1) dissolving the compound of Formula (I) in a solvent which is a non-aromatic non-halogenated hydrocarbon which can be substituted by one or more cyano groups; (2) adding a bromination agent selected from the group consisting of Br2 and N-bromoimides to the solution; and optionally (3) agitating the mixture at a temperature within the range of from room temperature to reflux temperature.

Abstract: The present invention relates to a method for producing 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine (lamotrigine) by cyclization reaction from &agr;-oxo-2,3-dichlorophenylacetamidino-aminoguanidino-hydrazone.